Nov. 15 at 11:38 AM
$CELU The financial situation is at a critical stage, which is why we need to finalize deals, generate revenue, and generate operating cash flow. The summer months often present lower revenue figures, so I believe and hope that the next two quarters will show substantial growth, which would also validate the products. The partnership with Genting Berhad gives me some peace of mind as long as it lasts. However, these small biotech companies are very fragile, compounded by a marked lack of interest from analysts and investors, who were left stung by the bursting of the speculative bubble in 2021. In any case, the two main projects are moving forward, and this gives me confidence, despite the high risks remaining.
